Generic drugs: How Sandoz wants to use patent expirations and shake up the weight loss market
Generic drug producer Sandoz is preparing for a billion-dollar market for counterfeit weight loss medications. Chief Financial Officer Steenberger outlines strategy and plans for expansion.
Sandoz, a Swiss company, is preparing to enter the market for generic versions of obesity medications, specifically those containing the active ingredient semaglutide, which is used in Novo Nordisk's Ozempic and Wegovy. The patent for semaglutide has expired in several countries, allowing Sandoz to launch its own versions, with plans to start in Brazil and Canada by the end of this year.
The company aims to become a leading provider of generics, with a potential market worth billions of dollars, and predicts that prices for obesity medications will drop significantly. Sandoz also develops biosimilars, complex copycat drugs made from living cells, and aims to more than double its net sales by 2035.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
